One already established drug in this context is bortezomib, a proteasome inhibitor dampening NF-κB activities, which resulted in a high response rate of up to 80% for MALT lymphoma but was not further followed due to hemato- and neurotoxicity [42,43]. Here, NFKB1 is linked to MALT lymphoma.